Almac Sciences of Northern Ireland has introduced a new business unit covering solid state chemistry in a move that addresses a missing link in its technology portfolio.
Pfizer is shifting its research focus to those diseases where its sees the potential for the biggest treatment improvements and profits, while dropping eight disease areas including cholesterol.
Indian pharmaceutical companies are making their first forays in the biotechnology arena, helping the market expand from a standing start at the beginning of the decade to reach a value of $2bn in 2006-7, according to a recent report from KPMG.
Indian pharmaceutical company Lupin Ltd has expanded into Africa by acquiring a 60 per cent stake Pharma Dynamics, a generics company and contract manufacturer based in Cape Town, South Africa.
China is the ideal destination for outsourcing, according to a report by PricewaterhouseCoopers (PwC) that has calculated rankings based on a range of parameters.
Germany-based Diapharm has launched a service allowing pharmaceutical manufacturers to perform joint third-party audits of active pharmaceutical ingredients (APIs).
Active pharmaceutical ingredient specialist Calyx Chemicals and Pharmaceuticals is planning an acquisition within the next two years, probably in the US or Europe, according to chief executive Smitesh Shah.
Pharmatek Laboratories has opened its highly-potent and cytotoxic facility located in San Diego, US, just over a year after announcing its move into this growth area of contract manufacturing.
Outsourcing-Pharma.com presents its latest round-up of new appointments, employment moves and personnel news in the pharmaceutical contract services sector.
India’s contract manufacturing market is expected to rocket forward over the next couple of years to reach a value of $2.46bn in 2010, according to a just-released report from KPMG.
Haupt Pharma has completed its merger with fellow German companies Amareg and Wülfing Pharma to create a major new force in the European contract development and manufacturing sector, with around 1,500 staff and an annual turnover of €180m.
Canada’s Patheon put in another quarter of robust revenues growth in its third quarter, which coupled with cost-reduction measures helped the firm trim its net loss to $14.7m, down 75 per cent on a year ago.
US fine chemical company Sigma-Aldrich said this morning that subsidiary SAFC Pharma has kicked off a $30m expansion plan for its active high-potency pharmaceutical ingredient (API) manufacturing facility in Madison, Wisconsin.
Canada’s PharmEng International almost tripled its turnover in the second quarter, as its acquisition of a Pfizer manufacturing facility at the end of 2007 transformed sales at contract manufacturing facility Keata Pharma.
A milestone payment from Bristol-Myers Squibb for the successful advancement of a project into clinical development, along with strong sales by its contract research and manufacturing services unit, prompted Albany Molecular Research Inc (AMRI) to hike...
Australia’s CSL Ltd has signed a $3.1bn agreement to acquire Talecris Biotherapeutics of the US and throw down the gauntlet to rival Baxter International in the plasma-based pharmaceutical sector.
Pharmaceutical company Enzon may hive off its entire specialty drugs division, including a manufacturing facility in Indianapolis, US, in the face of pressure from shareholder Carl Icahn.
Cambrex posted a 5 per cent hike in revenues in the second quarter, helped by its shift into contract controlled substance manufacture, although without favourable currency effects sales would have slipped back 2.6 per cent.
US Senator Sherrod Brown has fired off another broadside in his probe into pharmaceutical outsourcing, this time sending a request to Merck & Co “for further information on its heavy reliance on global outsourcing for the manufacture of pharmaceutical...
Contract manufacturer Nectar Lifesciences is to invest around RS 6bn ($141m) in a new bulk drug and pharmaceutical intermediate manufacturing facility in India's northern Punjab state.
Lonza of Switzerland is reaping the benefit of a shift away from bulk chemicals and towards custom manufacturing of high-value pharmaceuticals with a 13 per cent hike in sales in the first half of the year.
Outsourcing-Pharma.com presents its periodic round-up of personnel changes in the pharmaceutical outsourcing arena, with senior appointments at Bristol-Myers Squibb, Parexel and GVK Bio, amongst others.
Supply and manufacturing contracts signed during fiscal 2008 helped India's Hikal achieve first quarter sales of Rs 920m ($21.5m), up 63 per cent on the year-earlier comparable period.
Pharmaceutical companies in the developed world have already
shifted substantial manufacturing and clinical trial work to
emerging economies such as China and India, but a new study suggest
they are increasingly counting on these...
A deal to sell Pfizer's active pharmaceutical ingredient manufacturing (API) plant in County Cork, Ireland, has fallen through according to a statement by the US drug giant, placing over 180 production jobs under threat.
Outsourcing-Pharma.com presents its latest round-up of news in the
contract development and manufacturing sector, with updates from
Rentschler Biotechnologie, Eden Biodesign, Emcure Pharmaceuticals
and new start-up Appian Labs.
Visiongain's third annual conference on Pharmaceutical
Anti-counterfeiting Strategies kicks off next week, covering many
aspects of the problem from technological deterrents, regulatory
developments in the EU and US and the implications...
Slovenian drugmaker Krka has paid just under $1.6m (€1m) for 7.5
per cent stakes in two Chinese drug and chemicals firms, namely
Zhejiang Menovo Pharmaceuticals and Anhui Menovo Pharmaceuticals.
A US senator has asked the Food and Drug Administration (FDA) for a
probe into outsourcing of production for pharmaceuticals, as well
as ways to make drugmakers accountable for products which fail to
meet quality standards.
Patheon gave an update on its restructuring plans in Puerto Rico
yesterday, saying that its plant in Manati will be updated to
provide contract manufacturing of high-potency drugs and controlled
substances.
Introgen Therapeutics says advances in its biologics manufacturing
and storage technologies have allowed it to broaden the scope of
its contract manufacturing operations and set up a new unit called
Introgen Technical Services (ITS).
Japanese glass and chemical company Central Glass has found a swift
route into the contract manufacturing market for active
pharmaceutical ingredients (APIs) in Europe via the purchase of
Girindus' facility in Halle-Kuensebeck.
The new European Chemicals Agency (ECHA) opened its doors in
Helsinki this week, with questions raised immediately about its
ability to handle the thousands of registration requests required
under the controversial REACH legislation.
Canadian contract manufacturer and consultancy firm PharmEng
International has published its 2007 accounts, and says it remains
firmly focused on getting into the black in 2008.
China's Wuxi PharmaTech saw revenues race away across its divisions
in the first quarter of 2008, benefitting from the continued shift
towards outsourcing of manufacturing and laboratory functions by
the pharmaceutical industry.
Pharmaceutical manufacturers are now withdrawing from manufacturing
at an unprecedented rate, with four of the top 10 players
announcing major new outsourcing programmes in 2007, says IMS in a
new document which explores the implications...
Germany's Rentschler Biotechnologie and Boehringer Ingelheim have
inked a preferred partnership agreement to jointly offer customers
a more streamlined biopharmaceutical production option.
The US Food and Drug Administration has declared the country's
previously-tainted heparin supply to be "safe" due to
stronger testing and controls that are now in place. Meanwhile,
China continues to distance itself...
AMRI witnessed strong growth in two of its contract business during
the first quarter of 2008 although profit was impacted by its
dominant large-scale division, which lagged during the period.
SynCo Bio Partners has completed production of AG011 for ActoGenIX,
enabling the latter firm to begin examining it in patients
suffering from ulcerative colitis (UC).
Agilent Technologies is expanding its nucleic acid active
pharmaceutical ingredient (API) manufacturing facility in Boulder,
Colorado, US, as the industry gravitates towards the
development of oligonucleotide-based drugs.
Bushu Pharmaceuticals, Japan's largest dedicated contract
manufacturer, has been going from strength to strength as Japan's
pharma outsourcing industry awakens.
2005 marked the real beginning of contract manufacturing in Japan,
which had been held back by an overly-cautious regulatory
environment and significant and unique quality and specification
demands in the marketplace.
Cambrex has experienced a jump in profitability for the first
quarter 2008, despite a decrease in sales, assisted by previous
cost-cutting initiatives.
Indena offers custom development by leveraging the expertise of a specialized team devoted to designing and developing processes and analytical methods....